ବେକ୍ସାଗ୍ଲିଫ୍ଲୋଜିନ

ବେକ୍ସାଗ୍ଲିଫ୍ଲୋଜିନ
Clinical data
Trade names	Brenzavvy, Bexacat
AHFS/Drugs.com	monograph
data	US DailyMed: Bexagliflozin;
Routes of; administration	By mouth
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol;
Chemical and physical data
Formula	C24H29ClO7
Molar mass	୪୬୪.୯୪ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl;
	InChI InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1; Key:BTCRKOKVYTVOLU-SJSRKZJXSA-N;

ବେକ୍ସାଗ୍ଲିଫ୍ଲୋଜିନ, (ଇଂରାଜୀ ଭାଷାରେ Bexagliflozin), ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ବ୍ରେନଜାଭଭି ଏହାର ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ମଧୁମେହ ଟାଇପ-୨ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୩] ଏହା ଉପ‌ଯୁକ୍ତ ଖାଦ୍ୟ ଏବଂ ବ୍ୟାୟାମ ସହିତ ବ୍ୟବହୃତ ହୁଏ ।^[୩] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯୋନୀପଥ ଖମୀର ସଂକ୍ରମଣ, ମୂତ୍ରନଳୀ ସଂକ୍ରମଣ ଏବଂ ପରିସ୍ରା ବୃଦ୍ଧି ହୁଏ ।^[୩] ଗମ୍ଭୀର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଡାଏବେଟିକ କିଟୋଏସିଡୋସିସ, ଅଙ୍ଗପ୍ରତ୍ୟଙ୍ଗ ଛେଦନ, କମ୍ ରକ୍ତ ଶର୍କରା, ଫୋର୍ନିନୟର ଗ୍ୟାଙ୍ଗ୍ରିନ୍ ଏବଂ ବୃକ୍‌କ ସମସ୍ୟା ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ ।^[୩] ଗର୍ଭାବସ୍ଥାର ଶେଷ ଭାଗରେ ବ୍ୟବହାର କରିବାକୁ ସୁପାରିଶ କରାଯାଏ ନାହିଁ ।^[୩] ଏହା ଏକ ସୋଡିଅମ୍-ଗ୍ଲୁକୋଜ୍ କୋଟ୍ରାନ୍ସପୋର୍ଟର୍ ୨ (SGLT2) ପ୍ରତିବନ୍ଧକ | ^[୩]

୨୦୨୩ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ବେକ୍ସାଗ୍ଲିଫ୍ଲୋଜିନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୩] ୨୦୨୩ ମସିହାରୁ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହାର ମୂଲ୍ୟ ସ୍ପଷ୍ଟ ହୋଇନଥିଲା ।^[୪]

ଆଧାର

↑ "Bexacat- bexagliflozin tablets tablet". DailyMed. 16 January 2023. Archived from the original on 21 January 2023. Retrieved 21 January 2023.
↑ "FDA Approves First Oral Treatment for Cats with Diabetes Mellitus". U.S. Food and Drug Administration (FDA). 8 December 2022. Archived from the original on 11 December 2022. Retrieved 11 December 2022. This article incorporates text from this source, which is in the public domain.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ ^୩.୭ ^୩.୮ "Archive copy" (PDF). Archived (PDF) from the original on 2023-03-06. Retrieved 2023-03-07.{{cite web}}: CS1 maint: archived copy as title (link)
↑ "FDA Approves New Drug for Type 2 Diabetes". Formulary Watch (in ଇଂରାଜୀ). Archived from the original on 7 February 2023. Retrieved 1 May 2023.

[PI2023-1] "Bexacat- bexagliflozin tablets tablet". DailyMed. 16 January 2023. Archived from the original on 21 January 2023. Retrieved 21 January 2023.

[FDA_Bexagliflozin-2] "FDA Approves First Oral Treatment for Cats with Diabetes Mellitus". U.S. Food and Drug Administration (FDA). 8 December 2022. Archived from the original on 11 December 2022. Retrieved 11 December 2022. This article incorporates text from this source, which is in the public domain.

[Label2023-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ ^୩.୭ ^୩.୮ "Archive copy" (PDF). Archived (PDF) from the original on 2023-03-06. Retrieved 2023-03-07.{{cite web}}: CS1 maint: archived copy as title (link)

[FW2023-4] "FDA Approves New Drug for Type 2 Diabetes". Formulary Watch (in ଇଂରାଜୀ). Archived from the original on 7 February 2023. Retrieved 1 May 2023.

[୧]

[୨]

[୩]

[୪]